Alice Mims, MD

• Myelodysplastic Syndromes
• Acute Myeloid Leukemia

I am a hematologist who specializes in treating patients suffering from acute and chronic myeloid diseases, particularly acute myeloid leukemia (AML). I was named to the Castle Connolly list of “Regional Top Doctors” in 2019, as well as being rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017.

I received my medical degree and Master of Science in Clinical Research (MSCR) from the Medical University of South Carolina and then completed a combined fellowship in medical oncology/translational research here at The Ohio State University, where I currently serve as an assistant professor in the Division of Hematology.

During my fellowship, I received the Conquer Cancer Foundation Young Investigator Award, the American Society of Hematology Clinical Research Training Institute Award and a T32 Research Training Grant from the National Institutes of Health. Since I’ve been on faculty, I have received the American Society of Hematology Clinical Scholar Award and the Alliance Foundation Clinical Scholar Award, both for research support.

As a member of the Leukemia Research Program at the OSUCCC – James, my research interests include studying the effectiveness of novel therapeutics on patients with AML and other myeloid neoplasms. I have authored multiple clinical trial proposals in AML and have been the site principal investigator (PI) for investigator-initiated and industry-supported AML studies in both upfront and relapsed/refractory disease.

I am currently the lead PI on a multi-center study investigating novel treatment in elderly AML patients though the Leukemia & Lymphoma Society Beat AML Master Trial. Additionally, my work has been published in several well-respected journals, including Molecular Pharmacology, Leukemia and Blood.

I feel privileged to be part of the Ohio State medical community, and I’m especially proud to contribute to the work we do here at the OSUCCC – James. We all share a common goal: to provide cutting-edge research that will lead to a cancer-free world and deliver superior, individualized care to each and every one of our patients.